Search Results 431-440 of 16839 for Antagonist

1. Heart Attack Clinical Trials - Mayo Clinic Research

   The purpose of this study is to determine if apixaban given for 6 months is safer than Vitamin K Antagonist (VKA) given for 6 months in terms of major ...

2. A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer - Mayo Clinic

   Prior treatment with CYP17 inhibitor (e.g., ketoconazole, abiraterone acetate, galeterone) or next generation androgen receptor antagonist including apalutamide ...

3. Publications - Stacey A. Rizza, M.D. - Mayo Clinic

   Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. J Virol. 2016 Apr ...

4. A Study to Evaluate the Effectiveness and Safety of CC-93538 to Treat Adults and Adolescents with Eosinophilic Esophagitis - Mayo Clinic

   systemic corticosteroid within 8 weeks of the first Screening Visit. 7. Treatment with a swallowed topical corticosteroid, leukotriene receptor antagonist, or

5. Publications - Michael F. Neblett, II, M.D. - Mayo Clinic

   Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas. Obstet Gynecol. 2023 May 01; 141(5):901-910. Epub 2023 Apr 05. View ...

6. A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants - Mayo Clinic

   only: Participants initiating any endothelin receptor antagonist (ERA) or phosphodiesterase-5 inhibitor therapies at index date or at therapy change must

7. Puberty blockers for transgender and gender-diverse youth - Mayo Clinic

   When taken regularly, GnRH analogues stop the body from making sex hormones. That includes testosterone and estrogen. Sex hormones affect: Primary sex ...

8. Chronic Intestinal Pseudo Obstruction de novo Clinical Outcomes Assessment

   ... antagonist (e.g., eluxadoline), loperamide] within 2 weeks prior to screening and during study participation. Pregnant women. Failure to be eligible to ...

9. Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant In HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, Or PALB2m Advanced Breast Cancer - Mayo Clinic

   Substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index, eg, warfarin (and other coumarin-derived vitamin K antagonist anticoagulants) and ...

10. Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 To < 18 Years of Age - Mayo Clinic

    ... antagonists [biologic or small molecule], during the treatment phases. Concomitant use of a CGRP antagonist, such as erenumab or fremanezumab, is prohibited.